Geron Corporation announced new data presented at the 67th American Society of Hematology $(ASH)$ 2025 Annual Meeting regarding its first-in-class telomerase inhibitor, RYTELO® (imetelstat). The oral and poster presentations included pooled analyses from the IMerge study population, which suggested that treatment-emergent cytopenias may be associated with clinically meaningful outcomes, such as increases in hemoglobin and transfusion independence, in patients with lower-risk myelodysplastic syndromes (MDS). Additional analyses provided insights into imetelstat's safety profile and its potential in myelofibrosis and advanced MDS/AML. The company stated that these findings support the ongoing investigation of imetelstat as a treatment option for eligible patients with lower-risk MDS. The results have already been presented and are available on Geron's website.